Page last updated: 2024-10-15

hypoxanthine arabinoside

Description

hypoxanthine arabinoside: metabolite of adenine arabinoside used in therapy of ocular herpes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135410268
CHEMBL ID2092757
SCHEMBL ID1738548
MeSH IDM0051668

Synonyms (35)

Synonym
hypoxanthine arabinoside
9-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1h-purin-6-one
ara-inosine
hypoxanthine 9-beta-d-arabinoribofuranoside
ara-hx
7013-16-3
hypoxanthine, 9-.beta.-d-arabinofuranosyl-
9-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one
07dm6ggm1v ,
nsc 405122
einecs 230-295-3
unii-07dm6ggm1v
ara-h
hypoxanthine, 9-beta-d-arabinofuranosyl-
6h-purin-6-one, 9-beta-d-arabinofuranosyl-1,9-dihydro-
9-beta-d-arabinofuranosyl-1,9-dihydro-6h-purin-6-one
CHEMBL2092757
9-pentofuranosyl-3,9-dihydro-6h-purin-6-one
SCHEMBL1738548
9-ss-d- arabinofuranosylhypoxanthin
UGQMRVRMYYASKQ-UHTZMRCNSA-N
9-.beta.-d-arabinofuranosyl-1,9-dihydro-6h-purin-6-one
6h-purin-6-one, 9-.beta.-d-arabinofuranosyl-1,9-dihydro-
9-(b-d-arabinofuranosyl) hypoxanthine
mfcd01103251
AKOS027382864
9-((2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1h-purin-6(9h)-one
9-.beta.-d-arabinofuranosylhypoxanthine
arainosine
9-((2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,9-dihydro-6h-purin-6-one
AS-79085
A855714
9-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-purin-6-one
9-beta-d-arabinofuranosyl hypoxanthine
DTXSID90859029

Bioavailability

ExcerptReference
" In Long Evans rats, orally administered [8-14C]ara-M (10 mg/kg) was well absorbed but extensively metabolized to hypoxanthine arabinoside (ara-H), hypoxanthine, xanthine, uric acid, and allantoin."( Metabolic disposition and pharmacokinetics of the antiviral agent 6-methoxypurine arabinoside in rats and monkeys.
Burnette, TC; De Miranda, P; Koszalka, GW; Krenitsky, TA, 1991
)

Dosage Studied

ExcerptReference
" Analysis of the dose-response data by a double reciprocal plot method indicated that the antagonism was competitive."( Deoxyadenosine antagonism of the antiviral activity of 9-beta-D-arabinofuranosyladenine and 9-beta-D-arabinofuranosylhypoxanthine.
Drach, JC; Shipman, C; Smith, SH, 1978
)
" Rats dosed intraperitoneally or orally with ara-DMAP excreted unchanged ara-DMAP and one major metabolite, 6-methylaminopurine arabinoside (ara-MAP), in the urine."( Metabolism and pharmacokinetics of the anti-varicella-zoster virus agent 6-dimethylaminopurine arabinoside.
Koszalka, GW; Lambe, CU; Nelson, DJ; Resetar, A; Spector, T, 1992
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID70686Optimum concentration for differentiation of friend erythroleukemia cells1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
AID70684Inhibition of Cellular Replication of friend erythroleukemia cells1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
AID70559Percent benzidine-positive cell differentiation in friend erythroleukemia cells1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (73.33)18.7374
1990's5 (16.67)18.2507
2000's1 (3.33)29.6817
2010's2 (6.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1 Study of Heat/Phenol-Killed, E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 (EMP 123) in Healthy Volunteers Followed by Subjects Allergic to Peanuts (CoFAR 1)[NCT00850668]Phase 115 participants (Actual)Interventional2009-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]